Table 1 Summary of co-infection of EBV and HPV in several malignancies
From: Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis
Tumor type | Co-infection | Subtype of HPV | EBV product(s) | Reference |
|---|---|---|---|---|
NPC | 15% (Iran) | 6/11, 16/18 | EBER | [30] |
| Â | 34% (Morocco) | 16, 31, 45, 48 | EBER | [31] |
| Â | 42% (China) | 18 | EBER | [32] |
Cervical cancer | 31.8% | 16, 18, 58 | EBER | [39] |
|  | 12.5%–69% | 16, 18 | BALF1, BARF-1, LMP1 | [59] |
|  | 21.2%–64.3% | 16, 18 | EBNA3B | [60] |
Breast cancer | 35% | 16, 18, 33 | LMP1, EBNA-1 | [21] |
Prostate cancer | 8.8% (Sweden) | 18 | EBER | [88] |
| Â | 37% (United States) | 18 | EBER, EBNA-1 | [89] |